CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain control, today announced that it has been awarded a new European Patent covering 30 European countries, including EU major market countries (G5). This new patent significantly broadens and extends Javelin’s patent protection for Dyloject, its lead drug candidate. European Patent No. 1 574 221 entitled Stable Injectable Compositions, extends Dyloject’s European patent life and exclusivity from 2014 into 2024. A patent application corresponding to the newly issued European patent is pending in the United States.
